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Abstract
Background: Diagnosis and follow up of CanL is difficult since the range of clinical signs is varied and
seroprevalence is high in endemic areas. The aims of this study were: i) demonstrate the advantages of Leishmania
qPCR to diagnose and control CanL and highlight its prognostic value and ii) propose guidelines for tissue
selection and infection monitoring.
Findings: This study included 710 dogs living in an endemic area of leishmaniasis. Forty percent (285/710) exhibited
clinical signs consistent with CanL. Infection was detected in 36.3% (258/710) of the dogs of which 4.5% (32/710)
were detected by qPCR, 16.2% (115/710) detected by ELISA and 15.6% (111/710) tested positive for both tests. Only
17.9% (127/710) of the dogs were classified sick (affected) with CanL.
All symptomatic dogs with medium or high ELISA titers were qPCR-positive in blood samples. All dogs with
inconclusive or low ELISA results with high or medium qPCR parasitemia values developed the disease. Seventy one
percent of asymptomatic ELISA-positive dogs confirmed by qPCR (medium to high parasitemia) developed the disease.
Bone marrow or lymph node aspirate should be selected to ensure the absence of the parasite in asymptomatic
dogs: 100-1,000 parasites/ml in bone marrow are detectable in blood, whereas lower parasite loads are usually
negative. Almost 10% of negative samples in blood were positive in conjunctival swabs.
Conclusions: Because qPCR allows parasite quantification, it is an effective tool to confirm a diagnosis of CanL in
(i) cases of inconclusive ELISA results, (ii) when the dog has not yet seroconverted, or (iii) for treatment monitoring.
Findings
Leishmaniasis is one of the main zoonosis worldwide and
in some countries it is a reason of concern for public
health. Canine leishmaniasis (CanL) is of great impor-
tance in veterinary medicine since dogs are believed to be
the main reservoir of this parasite for humans [1]. It is
endemic along the Mediterranean basin, parts of east
Africa, India, Central and South America and the inci-
dence of infection is currently spreading to non endemic
areas towards the north of Europe [2] and recently emer-
ging in North America [3]. In addition, other species
have come to be infected, such as cats [4], and horses [5].
Wild canids are competent reservoirs of Leishmania [6],
increasing the risks for humans to acquire the disease in
endemic areas. Therefore, there has been a great interest
in the development of new diagnostic tests.
Diagnosis of CanL is fairly difficult, since dogs manifest
a very varied range of clinical signs. In CanL, infection
does not equal to having the clinical disease due to a
high prevalence of subclinical infections [7,8]. Moreover,
it is specially challenging in endemic areas where sero-
prevalence rates are high [7]. Epidemiological studies in
endemic zones of CanL, by means of molecular techni-
ques, have shown that the prevalence of infection in the
canine population by Leishmania is considerably higher
than seroprevalence [8]. There are several diagnostic
tests for CanL, but the correct interpretations of these
are of great importance to make an accurate diagnosis of
the disease [9]. Therefore, the aims of this study were:
i) to demonstrate the advantages of the quantitative PCR
of Leishmania (qPCR) to diagnose and control the dis-
ease and highlight its prognostic value and ii) propose a
guideline for the tissue of choice to be analyzed in each
case, as well as a guideline for monitoring the disease.
The study included 710 dogs from the LUPA Project
(7 PM; subWP canine leishmaniasis). The LUPA project
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study common complex human diseases using the dog
as animal model. The UAB leads the subworkpackage
focusing on canine leishmaniasis. All samples had
informed owner consent. Data from medical history
including physical exploration, clinical biochemistry and
complete blood count were collected for most of the
cases. Both anti-Leishmania ELISA and qPCR were
performed on serum and blood samples, respectively.
Serologies were performed at UNIVET
® using serum
samples that were tested using INGEZIM Leishmania,
an enzyme-linked immunoassay (ELISA) provided by
Ingenasa (Madrid, Spain), with some modifications. Pre-
sence of antibodies against Leishmania was determined
using anti-dog IgG as conjugate, following the recom-
mendations of the manufacturer as described elsewhere
[10]. qPCR was performed at the Servei Veterinari de
Genètica Molecular of Universitat Autònoma de Barce-
lona as described by Francino et al. [11]. Table 1 offers
the cutoff values for both ELISA and qPCR tests.
Dogs were monitorized from February 2007 until
March 2010 and, according to the recorded data men-
tioned above, they were classified as affected or unaf-
fected by the disease.
In 112 out of 710 dogs qPCR was additionally per-
formed in at least one alternative tissue to detect infec-
tion of Leishmania (i.e. bone marrow, lymph node
aspirate, biopsy and lesional or conjunctival swabs), pro-
viding useful information to support the tissue of choice
for diagnosing CanL.
All data was compiled with Excel (Microsoft). The differ-
ence between groups was tested for significance by Chi-
squared analysis. A p value < 0.05 was considered as statis-
tically significant. For the observed prevalence, 95% confi-
dence interval (CI) was calculated. Differences between
proportions were calculated using Chi-squared Yates cor-
rection. Test characteristics such as sensitivity, disease pre-
valence as well as positive predictive power, were analyzed
from a 2 × 2 table using ROC curve analysis. All data was
analyzed using MedCalc Software [12,13].
qPCR prognostic value
Forty percent (285/710) of the dogs exhibited clinical signs
consistent with CanL. Overall detection of the parasite by
ELISA and/or qPCR was found in 36.3% (258/710) of the
samples, but only 17.9% (127/710) of the dogs were classi-
fied as affected of the disease. These results differ from
higher values of prevalence showed in other studies where
more tissues were analyzed in each dog [7], but reinforce
the statement that further specific diagnostic tests such as
serology and qPCR should be performed in order to reach
a correct diagnosis. Treatment of dogs just based on few
compatible clinical signs is not recommended, especially
in endemic areas.
In endemic areas, a large part of the canine population
is exposed to the parasite (positive serological results are
expected) compared with the smaller proportion of dogs
that eventually develop disease [7]. These results are also
confirmed in our study; in which seroprevalence was of
31.8% (226/710) but only 50% of these dogs (113/226)
were classified as affected of CanL. Serology titers remain
high for a longer period of time before antibodies levels
decrease [14]. Moreover, false positive results in serology
tests can occur due to cross reactivity with other patho-
gens [8]. On the other hand, dogs remain seronegative
during variable time periods after the infection with
Leishmania [15]. Intervals for seroconversion on natu-
rally infected dogs can take from 1 to 22 months (median
5 months), and from 1 to 6 months (median, 3 months)
for experimentally infected dogs [16]. Therefore, serology
alone has a limited predictive value because the results
m a yb ea f f e c t e db yp e r s i s t e n ta n t i b o d i e so ri n m u n o s u -
pression. This statement correlates with our results
because we found that 84.3% (97/115) of the dogs, who
had positive serologies and negative qPCRs, were classi-
fied as unaffected of CanL. Detection and accurate para-
site quantification of the qPCR is an effective help in the
CanL diagnosis, mostly in cases of uncertain serology
results or when the dog has still not seroconverted.
Prevalence according to qPCR was lower than seropreva-
lence in our study (20.1% (143/710) but the majority of
the dogs were classified as affected of the disease [67.8%
(97/143)]. In conclusion, qPCR has a higher positive pre-
dictive value (67.8% vs. 50%; p value: 0.001) that will give
us confidence when looking at test results.
All the dogs analyzed with clinical signs and medium
or high positive ELISA titers were qPCR positive in
blood samples, except those that received previous
Table 1 Categories for cutoff values of qPCR and ELISA
qPCR result Parasites/ml of blood Parasites/ml of bone marrow ELISA result Titer (%)
Negative 0 0 Negative < 20
Low positive 0-10 0-100 Uncertain* 20-35
Medium positive 10-100 100-1,000 Low positive 35-80
High positive 100-1,000 1,000-10,000 Medium positive 80-150
Very high positive > 1,000 > 10,000 High positive > 150
* This category was incorporated for the purpose of this study based on previous data (data not shown).
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which the tissue of choice should be a swab of the der-
matological lesion. In dogs with clinical signs, but low
or uncertain ELISA titers, the qPCR has a significant
prognostic value. In our study, 100% of symptomatic
dogs with inconclusive ELISA results (uncertain or low
positive), but with patent parasite detection (high or
medium parasitemia measured with qPCR) develop the
disease (Figure 1).
In dogs without clinical signs, the qPCR also has an
important prognostic value since 71.4% of asymptomatic
ELISA-positive dogs confirmed by qPCR with medium
to high parasitemia values will end up with patent
leishmaniasis.
As a conclusion, dogs whose parasitemia range from
medium to high or very high positive are sick or even-
tually will become sick with CanL.
The tissue of choice
Due to the varied tropism that the parasite exhibits
regarding different tissues, the quantity of the parasite is
different and oscillates among them [7]. It is important
that the clinician chooses the most informative one in
each case since qPCR can be performed on different tis-
sues such as blood, bone marrow, lymph node, body
fluids, histopathology samples or conjunctival swabs.
To ensure the absence of the parasite in dogs without
clinical signs, the sample of choice is bone marrow or
lymph node aspirate since it is been proved to be the most
sensitive ones [17]. Moreover, blood is a valid tissue to per-
form routine qPCR analysis of CanL to evaluate response
to the treatment. In our study, we found that in few sam-
ples in which both blood and bone marrow were analyzed,
77.8% (7/9) of the blood samples detected Leishmania
while 88.9% (8/9) of the bone marrow did. The difference
corresponds to two dogs that were asymptomatic and had
very low titers in bone marrow (2 parasites/ml) and nega-
tive titers in peripheral blood. Parasite loads equal or
greater than 100-1,000 parasites/ml in bone marrow
are detectable in blood, whereas lower parasite loads
(1-100 parasites/ml in bone marrow) are usually negative
in blood, since there is a correlation between both tissues
(bone marrow usually being higher than blood). In this,
way blood is a valid tissue for monitoring treatment effi-
cacy despite that the first qPCR diagnosis has been
performed in bone marrow.
Almost 10% (8/83) of samples which were negative in
blood were positive in conjunctival swab. This result
correlates with other study that reported that 83% of the
dogs experimentally infected with L. infantum were
already positive by PCR of conjunctival swabs at
6 weeks after infection, whereas only 17% of the buffy
coat samples obtained at the same time were found to
be positive [15]. Prevalence values increase if the dog
shows ocular signs such as conjunctivitis, uveitis, ble-
pharitis or periocular alopecia. The prevalence of ocular
lesions in dogs with leishmaniasis range from 16% to
80% according to various studies [18,19]. Therefore, the
tissue of choice in cases of ocular signs is conjunctival
swab. It could also be used for early diagnosis since sen-
sitivity is superior to serologic testing or parasite culture
[15] and samples are obtained in a less invasive manner.
In the same way, lesional swab is recommended when
only dermatological lesions are present. Other studies
report that 65% of the dogs were found to be PCR posi-
tive for skin lesions compatible with Leishmania [15].
All together, we suggest guidelines for the tissue of
choice for qPCR given prior clinical signs and ELISA
results (Figure 2).
Monitoring CanL
In cases of positive qPCR it is recommended to monitor
the parasite load one month after treatment to evaluate
its response. If parasite titer decreases, treatment is
effective and a new qPCR control is just recommended
at the end of treatment (6-12 months). None of the cur-
rent anti-leishmanial drugs that are being used have
proved to induce parasitological remission in dogs since
Dogs with clinical signs 
compatible with CanL 
40.1% (285/710)
UNCERTAIN 
9.8%  (28/285)
LOW
7.4% (21/285)
100% 
(9/9)
Dogs without clinical 
signs compatible with 
CanL 
59.9% (425/710)
POSITIVE
20.2 % (86/425)
71.4%
(5/7)
Serology qPCR Dogs who will develop the disease 
High parasitemia 
28.6%(6/21)
Medium parasitemia 
10.7% (3/28)
High parasitemia 
57.1% (4/7)
Medium parasitemia 
42.9% (3/7)
Figure 1 Prognostic value of the qPCR in uncertain cases of canine leishmaniasis.
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cases [20,21]. If the parasite load still remains positive,
even after treatment, the clinician should evaluate a dif-
ferent treatment for the disease or the possible presence
of co-infections or other diseases [22]. qPCR is an effec-
tive tool to monitor treatment efficacy especially in
those cases were repeated treatments are needed and to
detect early possible relapses to avoid clinical disease.
As a preventive measure, annual screening is recom-
mended for all dogs, especially those living in endemic
areas.
Conclusions
In conclusion, due to the fact that qPCR allows quantifi-
cation of parasite load in a precise manner, it could be
an effective tool to confirm a diagnosis of canine leish-
maniasis mostly (i) in those cases were serology is
inconclusive, (ii) in cases where the dog has not yet ser-
oconverted, (iii) for treatment monitoring. Dogs whose
parasitemia range from medium to high or very high
positive are sick or eventually will become sick of CanL.
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